(Q37584094)

21 August 2017

title

A review of the efficacy and tolerability of venlafaxine (English)

1 reference

21 August 2017

M Dierick

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

21 August 2017

1 reference

21 August 2017

volume

12 Suppl 4

1 reference

21 August 2017

page(s)

307s-13s

1 reference

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2897%2983310-X

7 January 2021

Sertraline 50 mg daily: the optimal dose in the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2897%2983310-X

7 January 2021

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2897%2983310-X

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2897%2983310-X

7 January 2021

Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-hour monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2897%2983310-X

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2897%2983310-X

7 January 2021

Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2897%2983310-X

7 January 2021

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2897%2983310-X

7 January 2021

Progress in psychiatry (2).

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2897%2983310-X

7 January 2021

Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2897%2983310-X

7 January 2021

10.1016/S0924-9338(97)83310-X

Identifiers

DOI

1 reference

21 August 2017

1 reference